These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29263689)

  • 1. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.
    Giamberardino MA; Affaitati G; Costantini R; Cipollone F; Martelletti P
    J Pain Res; 2017; 10():2751-2760. PubMed ID: 29263689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
    Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erenumab for episodic migraine prophylaxis.
    Overeem LH; Neeb L; Reuter U
    Expert Rev Neurother; 2019 Aug; 19(8):751-757. PubMed ID: 30614741
    [No Abstract]   [Full Text] [Related]  

  • 6. A Controlled Trial of Erenumab for Episodic Migraine.
    Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
    N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
    Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of erenumab in the treatment of migraine.
    Andreou AP; Fuccaro M; Lambru G
    Ther Adv Neurol Disord; 2020; 13():1756286420927119. PubMed ID: 32523630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies for the prevention of migraine.
    Raffaelli B; Neeb L; Reuter U
    Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
    [No Abstract]   [Full Text] [Related]  

  • 11. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
    Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erenumab for episodic migraine.
    Datta A; Gupta S; Maryala S; Aggarwal V; Chopra P; Jain S
    Pain Manag; 2022 Jul; 12(5):587-594. PubMed ID: 35313740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG; Smith SM; Gums JG
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [No Abstract]   [Full Text] [Related]  

  • 17. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries.
    Ohlsson L; Haanes KA; Kronvall E; Xu C; Snellman J; Edvinsson L
    Cephalalgia; 2019 Dec; 39(14):1745-1752. PubMed ID: 31366221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Mullin K; Kudrow D; Croop R; Lovegren M; Conway CM; Coric V; Lipton RB
    Neurology; 2020 May; 94(20):e2121-e2125. PubMed ID: 31932515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
    Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
    Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
    Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.